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Abstract
Background: Smoking cessation following hospitalization for Acute Coronary Syndrome (ACS) significantly
reduces subsequent mortality. Depressed mood is a major barrier to cessation post-ACS. Although existing
counseling treatments address smoking and depression independently in ACS patients, no integrated treatment
addresses both. We developed an integrated treatment combining gold standard cessation counseling with
behavioral activation-based mood management; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS).
The purpose of this pilot randomized controlled trial was to test feasibility, acceptability, and preliminary efficacy
of BAT-CS vs. Standard of Care (SC).
Methods: Participants were recruited during hospitalization for ACS and were randomly assigned to BAT-CS or
SC. The nicotine patch was offered in both conditions. Smoking, mood, and stress outcomes were collected at
end-of-treatment and 24-week follow-up.
Results: Fifty-nine participants (28 BAT-CS, 31 SC) were recruited over 42 weeks, and assessment completion was
above 80% in both conditions. Treatment acceptability and fidelity were high. At 24 week follow-up adjusted odds
ratios favoring BAT-CS were 1.27 (95% CI: 0.41–3.93) for 7-day point prevalence abstinence and 1.27 (95% CI: 0.42–3.82)
for continuous abstinence. Time to first smoking lapse was significantly longer in BAT-CS (62.4 vs. 31.8 days, p = 0.03).
At 24-weeks, effect sizes for mood and stress outcomes ranged from η2partial of.07–.11, with significant between
treatment effects for positive affect, negative affect, and stress.
Conclusions: The design of this study proved feasible and acceptable. Results provide preliminary evidence that
combining behavioral activation with standard smoking cessation counseling could be efficacious for this high risk
population. A larger trial with longer follow-up is warranted.
Trial registration: NCT01964898. First received by clinicaltrials.gov October 15, 2013.
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Background
Smoking cessation following an Acute Coronary Syn-
drome (ACS) requires increased attention. ACS patients
smoke at a significantly higher rate (29–37% [1–3]) than
the US population (20% [4]). Without intensive treatment,
most patients return to smoking within a year following
ACS [5]. Further, ACS patients are at significantly higher
risk for recurrent ACS and death if they continue to
smoke, with successful smoking cessation reducing
mortality by 36% [6].
Depressed mood is also a major concern following
ACS. Clinical and sub-clinical depression are much
more common in ACS patients than the general popula-
tion [7]. Symptoms of depression, even when mild, inde-
pendently predict post-ACS morbidity and mortality [8].
The American Heart Association now recognizes de-
pression as a major risk factor following ACS [7]. The
two cardinal symptoms of clinical depression are nega-
tive mood and anhedonia (i.e., lack of interest/pleasure
in activities, lack of positive affect). Recent evidence sug-
gests that anhedonia symptoms may be particularly pre-
dictive of poor outcomes following ACS, with multiple
findings suggesting anhedonia is more predictive than
negative mood variables (e.g., [9]).
There are well established bi-directional relationships
between smoking and depression/anhedonia in the gen-
eral population (e.g., [10]). A recent meta analysis of 20
longitudinal studies concluded that those with depres-
sion symptoms at the time of ACS had significantly
higher smoking rates post-ACS [11]. Further, smoking
status partially mediates the relationship between de-
pression and post-ACS mortality [12].
Although there are counseling treatments that address
smoking and depression independently in ACS patients,
to our knowledge there is no integrated treatment that ad-
dresses both. A single, integrated treatment targeting both
depressed mood and smoking could be highly effective in
reducing post-ACS mortality. Behavioral activation (BA)
may be the ideal mood management intervention for such
an integrated treatment.
BA is a counseling intervention that aims to improve
mood by re-engaging patients with healthy sources of
positive reinforcement in their environment. Patients
and counselors work collaboratively to set individually
tailored “activation goals” that are pleasurable and/or
consistent with the patient's personal goals and values.
Activation goals can include social outings, behaviors
that advance vocation/education, exercise, hobbies, and
explicit health behavior change targets (e.g., activities
consistent with smoking cessation [13]).
BA efficacy has been clearly established for the treat-
ment and prevention of depression in psychiatric [14]
and medical populations (e.g., [15, 16]). BA can be deliv-
ered with fidelity by nurse-level practitioners [17],
directly targets anhedonia [18], and can be effective in
relatively few sessions [19]. Most importantly, recent
work suggests that BA can facilitate and maintain health
behavior changes among those with depressed mood
(e.g., [20–22]), including a randomized trial indicating
that adding BA-based mood management to standard
smoking cessation treatment may be effective for
smokers with elevated depression symptoms [23].
Study aims
We systematically developed a counseling intervention
that integrates standard smoking cessation counseling
with BA-based mood management for post-ACS
smokers; Behavioral Activation Treatment for Cardiac
Smokers (BAT-CS). The present study reports the re-
sults of a pilot randomized controlled trial comparing
the effects of BAT-CS to a Standard-of-Care control on
smoking abstinence, as well as mood and stress. Our pri-
mary aims were to determine: a) feasibility/acceptability
of the trial protocol and b) if results warrant a fully pow-
ered efficacy trial.
Methods
Participants
Participants were hospitalized smokers with ACS (diag-
nosis of unstable angina, ST and non-ST elevation MI)
who were smoking before their hospitalization. Inclusion
criteria were: 1) ACS diagnosis documented in the med-
ical record, 2) smoking ≥3 cigarettes per day immedi-
ately prior to hospitalization, 3) age 18–75, 4) English
fluency, 5) regular telephone access, 6) living within a 1
hour drive of the admitting hospital, and 7) willingness
to “strongly consider” an attempt to quit smoking at dis-
charge. We used a cut-off of ≥3 cigarettes per day to in-
clude regular, daily smokers who could benefit from the
nicotine patch. Exclusion criteria were: 1) evidence of
limited mental competency, 2) current psychosis, bipolar
disorder, borderline personality disorder, or suicidality
(based on chart review and self-report), 3) expectation
that the participant would not live through the study
period, or 4) regularly attending counseling for depres-
sion or smoking cessation and plans to continue this
counseling after discharge (which would duplicate BAT-
CS treatment).
Sample size and power
This study was designed as a pilot to examine treatment
feasibility/acceptability and preliminary efficacy (i.e., it was
not designed to be fully powered or to establish efficacy).
Specifically, with an analyzed sample size of 59 this study
was underpowered (power = 47%) to detect a medium
effect (i.e., OR = 2.50) on dichotomous smoking out-
comes. There was greater, (although still not sufficient)
power to estimate intervention effects on secondary
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outcomes: there was 75% power to detect a medium effect
(i.e., partial eta squared = 0.13) on longitudinal continuous
outcomes and 70% power to detect a medium effect (i.e.,
HR = 0.20) on survival analysis outcomes. Thus, primary
and secondary outcome results will be presented as pre-
liminary, and we present effect sizes in addition to signifi-
cance tests. All efficacy outcomes, especially dichotomous
outcomes, should be interpreted with caution.
Procedures
All procedures were approved by The Miriam Hospital
institutional review board. Participants were recruited
from inpatient cardiac units at The Miriam and Rhode
Island Hospitals in Providence, RI during 2013–14.
Potential participants were first identified through
electronic medical record reviews and medical staff
referrals. Patients appearing to meet study criteria were
approached by a research assistant regarding participa-
tion during their inpatient stay for ACS. Interested pa-
tients were screened for eligibility. Those that passed
screening and remained willing to participate provided
signed informed consent.
In-hospital smoking cessation counseling
All participants received one 50-min smoking cessation
session in the hospital, which did not include any BA or
mood management content. This session was guided by
the latest version of the Treating Tobacco Use and De-
pendence Clinical Guidelines [24] and a National Cancer
Institute self-help workbook (Clearing the Air) which
the participant kept. During this session, counselors pro-
vided a strong and personalized recommendation to quit
and discussed: 1) past attempts to quit, reframing at-
tempts as learning opportunities, 2) risks of smoking
and benefits of quitting in general and for cardiac pa-
tients, 3) personal reasons for quitting, 4) how to
recognize and avoid smoking triggers, 5) how to elicit
support for quitting, 6) tips for managing cravings, 7)
planning for a quit date, and 8) safety/efficacy of the
nicotine patch. Per treatment guidelines [24], brief mo-
tivational strategies were provided to those who
remained ambivalent about quitting.
Eight weeks of the nicotine patch were offered at dis-
charge if the patient was willing to make a quit attempt
and the patient’s physician approved. While use of the
nicotine patch appears to be generally safe for cardiac
patients [25], there are reports of increased risk to sub-
groups of ACS patients [26], and clinical practice guide-
lines [24] recommend that the patch is “used with
caution” in the 2 weeks following myocardial infarction.
Thus, physician approval was obtained before patch
provision. Dosing followed manufacturer recommenda-
tions (e.g., starting on 21 mg patch for those smoking
>10 per day and on 14 mg for those smoking ≤10 per
day). All participants who expressed interested in using
the patch were cleared by their physician for patch use.
Randomization
We used a computer generated (using R, Cran.R-projec-
t.org) permuted block randomization procedure, with
small, random sized blocks. Randomization was strati-
fied by counselor and elevated symptoms of depression
(i.e., Patient Health Questionnaire-9 (PHQ-9) ≥ 10 vs.
PHQ-9 ≤ 9). The study statistician provided sequenced
randomization envelopes. The randomization envelopes
were opened by counselors following the completion of
each in-hospital smoking cessation session. Counselors
then immediately informed the participant of their treat-
ment condition.
Standard-of-care (SC)
The SC group received 5 mailings of print materials at 1,
3, 6, 9 and 12 weeks post-discharge. Materials were 10
smoking cessation educational brochures produced by
JourneyWorks Publishing (two sent at each time point).
The 10 brochures are: 1) Relapse Happens 2) Breaking
Nicotine Addiction, 3) 50 Things You Should Know
About Quitting, 4) How Quitting Smoking Affects Your
Body, 5) Quit Smoking Without Gaining Weight, 6) How
Quitting Smoking Helps Your Heart, 7) Top Ten Steps to
Quitting Smoking, 8) The Health Consequences of Smok-
ing, 9) How to Quit When You Have Tried Before, and
10) Adjusting to a Smoke Free Life. SC participants were
contacted by a master’s level health educator for brief
(5–10 min) “check-in” calls following each mailing. Calls
focused on whether the participant received and read
the written materials, general encouragement to quit
smoking, and participant questions about nicotine patch
use. There was no discussion of the importance of de-
pressed mood or goal setting in the SC condition.
The treatment provided in the SC condition is above
and beyond that provided by most US hospitals. How-
ever, the Joint Commission on Hospital Accreditation re-
cently released a new performance standard [27] which
encourages US hospitals to provide cessation counseling
before discharge, offer cessation pharmacotherapy at dis-
charge if medically appropriate, and assess smoking sta-
tus and provide some cessation support in the weeks
after discharge. SC meets all aspects of the Joint Com-
mission standard. Our choice of a strong control group
likely lowered our between group effect on smoking ces-
sation, however it provides a more clinically and scientif-
ically meaningful comparison.
Behavioral activation treatment for cardiac smokers (BAT-CS)
The BAT-CS manual was informed by the manual used
in the only published RCT of BA as an aid for smoking
cessation, as well as an ongoing RCT (R01DA018730)
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[23]. This existing manual was designed for non-
hospitalized smokers and was delivered in several
90 min in-person group sessions in a community clinic.
Our adaptation of this existing manual was required to
account for treatment setting (e.g., initiation while hos-
pitalized) and structure (i.e., fewer, shorter, individual
counseling sessions, mostly over the phone) to better fit
the needs and preferences of post-ACS patients. We
assessed needs and preferences of post-ACS smokers
through extensive mixed method interviews [28] and test
cases. Adaptation was also guided by clear meta-analytic
data on the dose of treatment needed for significant ef-
fects on smoking cessation in hospitalized cardiac pa-
tients [29, 30].
BAT-CS combines standard, guideline-driven smoking
cessation counseling with BA-based mood management
and goal setting techniques. BA has its underpinnings in
the behavioral model of depression and purports that de-
pression and related problem behaviors, such as smoking,
can be reduced by reconnecting patients with healthy
sources of positive reinforcement. BA accomplishes this
through collaboratively defined between-session “activa-
tion goals” (i.e., explicitly scheduled between-session
activities). In BAT-CS, activation goals had 3 targets: (1)
increasing pleasant and/or meaningful activities in order
to improve mood and facilitate smoking cessation, (2) in-
creasing activities consistent with a non-smoking lifestyle
(e.g., social outings in non-smoking settings with non-
smoking peers), and (3) developing specific steps to pre-
pare for and initiate a quit attempt. The BAT-CS manual
is available by request from the first author [31].
All patients randomized to BAT-CS were offered a mini-
mum of 5 post-discharge contacts at 1, 3, 6, 9, and
12 weeks. Session 2 (1 week post-discharge; 50 min) oc-
curred in-person at a research clinic or in the participant’s
home. Session 2 began with assessment of smoking status
and mood (using the 2-item Patient Health Questionnaire,
PHQ-2). If the patient was not smoking, the counselor re-
inforced their efforts, discussed successful strategies used
to stay quit, and problem-solved challenges to continued
abstinence. If the patient was smoking, any attempt to quit
or cut down was reinforced, and relapse causes were dis-
cussed. For smoking patients interested in making another
quit attempt, the counselor reviewed strategies to deal
with triggers and cravings, and a new detailed plan for
quitting was collaboratively developed. For smoking pa-
tients that were not interested in another quit attempt,
brief motivational techniques (as specified in clinical
guidelines [24]) were provided.
The counselor then reviewed the importance of ad-
dressing depressed mood after a hospitalization for ACS,
presented a rationale for BA, and assessed potential tar-
gets for activation goals. Content of activation goals was
determined through a personal values assessment [32]
and discussion of pleasant/meaningful activities re-
stricted due to ACS (post-ACS activity restriction has
been linked to poor mood and failure to quit smoking
[28]). The counselor and patient collaboratively agreed
on 2–4 activation goals to improve/maintain mood and
facilitate smoking cessation, to be completed before the
next session, and problem-solved barriers to completion.
At the end of session, the counselor provided a written
list of activation goals and solutions to barriers, and of-
fered to send the participant a between-session email or
text message reminder to complete their goals.
Sessions 3–6 (3, 6, 9, and 12 weeks post-discharge;
30 min) were conducted by phone to minimize partici-
pant burden and followed the same basic format: 1) as-
sess smoking status and depressed mood (using PHQ-2);
2) provide support for continued abstinence or smoking
cessation as described in session 2 above; 3) review ad-
herence to activation goals agreed upon in the previous
session and assess reasons for failure to complete goals;
4) collaboratively choose new activation goals; and 5)
problem-solve barriers to completion of new goals. Pa-
tients were offered a between-session email or text mes-
sage reminder to complete goals. Session 6 (12 weeks post
discharge), focused on maintenance of a high rate of be-
haviors that are pleasant, valued, and consistent with a
non-smoking lifestyle following counseling termination.
Up to 4 additional phone booster sessions were offered
(i.e. patient could choose to schedule or not) if the par-
ticipant self-reported high levels of depressed mood
(PHQ-2 ≥ 3) or relapse to smoking, or by participant re-
quest. The content of booster sessions was similar to
follow-up calls but focused on the issue that triggered
the booster session (e.g., if prompted by a high PHQ-2,
its primary focus was mood management). Booster ses-
sions were scheduled 1 week after any session where
high depression or relapse was reported and lasted about
15 min.
Treatment fidelity
All in hospital sessions and post-randomization BAT-CS
counseling sessions were conducted by the first author
(licensed clinical psychologist) and second author (clin-
ical psychology post-doctoral fellow supervised by the
first author). Note that although PhDs performed all
BAT-CS treatment in this pilot trial, manual content was
designed for use by bachelor’s level counselors.
Attendance was tracked in BAT-CS and engagement
with mailed written materials was tracked in SC.
Treatment fidelity checklists were completed by coun-
selors following the in-hospital smoking cessation ses-
sion in both conditions. Following each BAT-CS
session, counselors also completed treatment fidelity
checklists, recorded activation goals set, and recorded
participant self-report of the percent completion of
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each activation goal from the previous session (rated
from 0 to 100% completed).
Assessments
Participants completed the baseline assessment while
hospitalized. Follow-up assessments were completed at
end-of-treatment (12 weeks after hospital discharge) and
24 weeks post-discharge. Assessments were conducted
by study staff blind to treatment condition.
Sociodemographic, medical status, and smoking history
variables
At baseline (i.e., during hospital stay), participants self-
reported socio-demographics and smoking history. Ini-
tial medical status and history were obtained through
self-report and chart review. Nicotine dependence was
measured using the Fagerstrom Test for Nicotine De-
pendence (FTND [33]).
Feasibility
Design feasibility was determined by: 1) recruitment
rate, 2) percentage of those screened who qualified, 3)
percentage of those qualified who chose to participate,
and 4) percentage that completed follow-up assessments.
Treatment feasibility was determined by number of
post-discharge sessions attended in BAT-CS and number
of print materials read in SC.
Acceptability
Treatment acceptability was assessed in both conditions
at end-of-treatment using the Client Satisfaction Ques-
tionnaire (CSQ [34]), an established measure of patient
satisfaction with treatment quality, quantity, and proce-
dures. Scores range from 8 to 32 with higher scores indi-
cating greater satisfaction.
Smoking outcomes
The primary smoking outcome was 7-day point preva-
lence abstinence (7-day PPA), defined as no smoking at
all in the past 7 days, not even a puff. A breath sample
was collected at follow-up assessments if the participant
reported ≥7-days of abstinence. Carbon monoxide (CO)
level in the breath sample verified self-reported 7-day
PPA (< 10 ppm = abstinence). We made an a priori
choice of CO < 10 ppm to verify abstinence as recom-
mended by the most recent Society for Research on
Nicotine and Tobacco consensus statement [35]. We are
aware of some data suggesting that cutoffs as low as
3 ppm can increase certainty in determining smoking
abstinence [36, 37]. However, other work indicates that
for patients with Chronic Obstructive Pulmonary Dis-
ease (COPD) and other breathing disorders, these lower
cutoffs may lead to a high rate of false negatives and that
a cutoff of <10 ppm produces the most accurate results
in this population [38]. We knew a priori from our pre-
vious pilot data that a significant proportion of our sam-
ple in this trial would have COPD, asthma, and/or
shortness of breath due to heart failure. Thus, we main-
tained our a priori cut-off of CO < 10 ppm. Those who
reported abstinence from smoking cigarettes but did not
provide a breath sample or reported using other tobacco
products or electronic cigarettes containing nicotine
were considered smokers. We also report continuous ab-
stinence since hospital discharge, and time to first lapse
(i.e., first puff ) and time to first relapse (i.e., smoking on
7 consecutive days or smoking in 2 consecutive 7 day
periods), which were determined through timeline follow
back interviewing methods at each assessment.
Mood and stress outcomes
Depression symptoms were assessed using the Patient
Health Questionnaire-9 (PHQ-9) [39]. PHQ-9 scores
range from 0 to 27 with higher scores indicating more
depression symptoms. The standard cut-off on the
PHQ-9 (i.e., ≥10 indicates likely major depression) was
used to estimate the rate of major depression at baseline.
The ten item Positive Affect Negative Affect Scales
(PANAS) [40] assessed positive (PANAS-PA) and nega-
tive (PANAS-NA) affect at all time points. PANAS-PA
scores range from 5 to 25 with higher scores indicating
greater positive affect in the past week. PANAS-NA
scores range from 5 to 25 with higher scores indicating
greater negative affect in the past week. Perceived stress
was measured using the Perceived Stress Scale (PSS
[41]); scores range from 0 to 16 with higher scores indi-
cating greater stress over the past month. We included
stress as an outcome because it has been linked to poor
prognosis [42].
Potential confounders
We tracked nicotine patch use, engagement in cardiac
rehabilitation, and engagement in non-study provided
counseling or medication treatment for smoking or de-
pression during the study period. Note that we excluded
based on ongoing counseling for smoking cessation or
depression at baseline, but for ethical reasons, we did
not restrict participants from seeking out additional (i.e.,
outside the study) counseling treatment during study
participation. Thus, we have included non-study coun-
seling for smoking cessation or depression as potential
confounders.
BA mechanism
Behavioral activation (i.e., rate of active, pleasurable,
and/or goal directed behavior) was measured using the
Behavioral Activation for Depression Scale-Short Form
(BADS) [43]. Scores range from 0 to 54 with higher
scores indicating greater activation over the past week.
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Data analysis plan
As a preliminary step in analyzing outcomes, between
group differences in baseline characteristics, medical his-
tory, and psychosocial variables were compared using t-
tests, chi-squared tests, and Mann-Whitney U tests. Un-
adjusted smoking rates and unadjusted mood and stress
outcomes were summarized over time by group.
For smoking outcomes we considered nicotine patch
use, concurrent smoking counseling, and smoking medi-
cation use as potential confounders. For mood and stress
outcomes we considered cardiac rehabilitation attend-
ance (because cardiac rehabilitation improves mood),
concurrent depression counseling, and concurrent de-
pression medication treatment as potential confounders.
Inclusion of these covariates in the final model was de-
termined by model fit.
Using a series of longitudinal regression models imple-
mented with generalized estimating equations (GEEs), we
assessed effects of BAT-CS vs. SC on biochemically veri-
fied 7-day PPA at end-of-treatment and 24 weeks, as well
as the binary indicator of continuous abstinence since
hospital discharge at end-of-treatment and 24 weeks, spe-
cifying a logit link function. Models included robust
standard errors to adjust for repeated measures within
participant over time and adjusted for potential con-
founders identified a priori (final models presented below).
Interest was in estimating effects (odds ratios) and corre-
sponding 95% confidence intervals, rather than strict stat-
istical hypothesis testing.
Secondary smoking outcomes included time to first
lapse and time to first relapse. As these outcomes are
time to event data, survival analysis was used to model
the risk of lapsing/relapsing over time. In this case, each
participant contributes two outcome variables to the
model: T*i, time to first lapse/relapse and Ci, censoring
time. For participants who lapse/relapse before the end
of treatment, T*i < Ci; for those who don’t lapse/relapse
before end of treatment or who discontinue the study
protocol before lapsing/relapsing, T*i > Ci. Thus, the
model uses Ti = min (T*i, Ci) as the response for
each participant. Using a Cox model, we created the
hazard function (which can be thought of as the
number of lapses/relapses per patient-day of follow-
up time) as a function of a baseline hazard rate λ0(t)
and covariates X (t), including treatment assigned and
potential confounders.
Next, using a series of longitudinal regression models
implemented with GEEs [44] and identity link, we esti-
mated the effects of treatment on mean changes from
baseline in PHQ-9, PANAS-PA, PANAS-NA, PSS, and
the BADS at end-of-treatment and 24 weeks. Models ad-
justed for confounders identified a priori and baseline
value of the outcome. We also report PHQ-9 models
stratified by baseline depression.
Finally, correlations between changes in BADS from
baseline to end-of-treatment and 24 weeks and con-
current changes in other mood and stress outcomes
were estimated to assess consistency with the BA
model. We used spearman rank correlations which
are less sensitive to potential outliers, which is im-
portant in small samples.
All analyses were carried out using the intent to treat
(ITT) sample and run using SAS 9.3. Likelihood based
approaches were used for estimation. Models made use
of all available data in order to estimate effects, without
directly imputing missing values.
Results
Sample
One hundred thirty-nine patients were approached, 103
were screened for eligibility, 71 were eligible, and 65
consented to participate. One patient’s diagnosis was
changed to a non-ACS diagnosis before randomization,
thus, 64 patients were randomized. Three randomized
participants did not receive the intervention (one was
unexpectedly discharged to a residential rehabilitation
institution with a campus smoking ban for the treatment
period, two refused any treatment after discharge), and
two were considered ineligible post-randomization be-
cause their final discharge diagnosis was not ACS. Thus,
we report on the outcomes of 59 participants, 31 who
received SC and 28 who received BAT-CS. See Fig. 1 for
Consort Diagram which includes reasons for exclusion.
Table 1 presents baseline data by treatment condition.
No significant differences were observed between groups
on any variable in Table 1.
Feasibility and acceptability
74.1% of those approached completed screening. 91.5%
of those who passed screening consented. We recruited
for a total of 42 weeks, thereby recruiting 1.4 partici-
pants per week that were included in analyses. 93.2 and
84.7% of participants provided data at end-of-treatment
and 24 week assessments respectively (see Fig. 1). BAT-
CS participants completed an average of 4.5 (SD = 1.5)
post-discharge sessions. Booster sessions were utilized
by 32.1% of all BAT-CS participants. SC participants
self-reported reading an average of 7.4 (SD = 2.3) of the
10 post-discharge brochures. Mean CSQ satisfaction
score was 31.1 (SD = 1.3) in SC and 30.5 (SD = 2.7) in
BAT-CS, a non-significant between-group difference.
Treatment Fidelity
The treatment adherence checklist indicated that coun-
selors provided planned in-hospital smoking cessation
treatment components at a rate of 96.9% in SC and
97.3% in BAT-CS. There was no significant between-
group difference in in-hospital session adherence.
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Counselors reported providing an average of 97.0% of
planned treatment components during post-discharge
BAT-CS sessions. BAT-CS participants set an average
10.6 (SD = 3.6) activation goals during the course of
treatment. Average goal completion percentage was
72.7% (SD = 14.7%).
Potential confounders
There were no significant differences between groups in: 1)
use of study-provided nicotine patch (58.1% SC vs. 67.9%
BAT-CS), 2) use of non-study cessation medication (25.8%
SC vs. 15.4% BAT-CS), 3) engagement in concurrent smok-
ing cessation counseling (0.0% for both conditions), 4) at-
tendance at cardiac rehabilitation (38.7% SC vs. 38.5%
BAT-CS), 5) use of antidepressants (16.1% SC vs. 15.4%
BAT-CS), or 6) use of non-study depression counseling
(3.2% SC vs. 7.7% BAT-CS). Although there were not be-
tween group differences, variables were still considered po-
tential confounders of the treatment effect and were thus
included as part of the final model when model fit indicated
inclusion.
Smoking outcomes
Unadjusted smoking outcomes (i.e., without covariates,
assessment completers only) indicate that 48.0% of BAT-
CS vs. 44.8% of SC participants achieved 7-day PPA at
end-of-treatment and that 45.8% of BAT-CS vs. 42.3% of
SC participants achieved 7-day PPA at 24 week follow-
up. In addition, in unadjusted analyses 44.0% of BAT-CS
vs. 33.3% of SC participants were continuously abstinent
through end-of-treatment and 37.5% of BAT-CS vs.
Fig. 1 Consort diagram
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Table 1 Baseline participant characteristics, mean (SD) or %
BAT-CS (n = 28) SC (n = 31) Total (n = 59)
Demographics
Age (years) 53.9 (11.9) 57.1 (8.3) 55.6 (10.2)
Married or living with committed partner 53.6% 58.1% 55.9%
Female 17.9% 35.5% 27.1%
Race
Non-Hispanic Caucasian 89.3% 90.3% 89.8%
Non-Hispanic African American 3.6% 6.5% 5.1%
Hispanic Caucasian 7.1% 0% 3.4%
Multiracial 0% 3.2% 1.7%
Employed (full or part-time) 67.8% 58.1% 62.7%
Median yearly household income a $44,000 $35,500 $38,000
Some college education 46.4% 58.1% 47.5%
Medical History
Prior ACS event 21.4% 35.5% 28.8%
Co-morbidities
Heart Failure 10.7% 16.1% 13.6%
Diabetes 25.0% 35.5% 30.5%
COPD 25.0% 29.0% 27.1%
Previous Stroke 3.6% 3.2% 3.4%
Peripheral Artery Disease 17.8% 6.5% 11.9%
ACS Characteristics
Type of index ACS event
STEMI 42.9% 54.8% 49.2%
NSTEMI 46.4% 35.5% 40.7%
Unstable Angina 10.7% 9.7% 10.2%
Intervention
Cardiac Catheterization 100% 96.8% 98.3%
≥ 1 stents placed 78.6% 87.1% 83.1%
CABG 14.3% 6.5% 10.2%
Length of Hospital Stay (days) 3.6 (4.7) 3.6 (3.0) 3.6 (3.9)
LVEF <55% a 46.2% 53.3% 50.0%
Baseline Smoking
Cigarettes/day 15.8 (9.2) 16.9 (9.5) 16.4 (9.3)
Total years smoking regularly 35.1 (13.9) 41.1 (8.8) 38.3 (11.8)
≥ Monthly Other tobacco use 3.6% 9.7% 6.8%
≥ Monthly Electronic-Cigarette use 14.3% 9.7% 11.9%
FTND 4.7 (2.4) 4.8 (2.2) 4.8 (2.3)
Baseline Mood
Depressive Symptoms (PHQ-9) 6.8 (5.8) 7.0 (6.5) 6.9 (6.1)
PHQ ≥ 10 25.0% 29.0% 27.1%
Taking Antidepressant Medication 10.7% 9.7% 10.2%
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34.6% of SC participants were continuously abstinent
through 24 weeks.
Adjusted ITT rates of biochemically verified 7-day PPA
and continuous abstinence since hospital discharge at
end-of-treatment and 24 week assessments are presented
in Fig. 2. There were no significant treatment effects in ad-
justed outcomes over time. Final models adjusted for nico-
tine patch use and concurrent medication treatment
targeting cessation. At end-of-treatment adjusted odds
ratios favoring BAT-CS were 1.12 (0.37–3.40) for 7-day
PPA and 1.82 (95% CI: 0.62–5.40) for continuous abstin-
ence. At 24 weeks adjusted odds ratios favoring BAT-CS
were 1.27 (95% CI: 0.41–3.93) for 7-day PPA and 1.27
(95% CI: 0.42–3.82) for continuous abstinence.
Survival analysis results indicate that mean number of
days to first lapse after discharge was significantly greater
for BAT-CS vs. SC (62.4 vs. 31.8, p = 0.03). When model-
ing treatment effects on the risk of lapse after discharge,
Table 1 Baseline participant characteristics, mean (SD) or % (Continued)
Positive Affect (PANAS) b 13.7 (4.5) 14.6 (4.6) 14.1 (19.0)
Negative Affect (PANAS) b 9.7 (5.1) 7.6 (3.6) 8.6 (4.5)
Perceived Stress Scale 5.5 (3.7) 5.4 (2.8) 5.5 (3.2)
BADS 32.7 (12.7) 35.9 (10.8) 34.4 (11.7)
Note. ACS Acute Coronary Syndrome, COPD Chronic Obstructive Pulmonary Disease, STEMI ST segment elevation myocardial infarction, NSTEMI non-ST segment
elevation myocardial infarction, CABG Coronary artery bypass graft surgery, LVEF Left ventricular ejection fraction, FTND Fagerstrom Test for Nicotine Dependence,
PHQ-9 Patient Health Questionnaire-9, PANAS Positive Affect Negative Affect Scales, BADS Behavioral Activation for Depression Scale-Short Form
an = 56
bn = 58
Fig. 2 Adjusted smoking rates over time
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results indicate significant effects, such that for those ran-
domized to BAT-CS, risk of lapse was 0.38 times that of
those in SC (HR = 0.38, 95% CI: 0.17–0.82, p = 0.01). Al-
though mean days to first relapse favored BAT-CS partici-
pants (71.2 vs. 47.4 days; p = 0.08), there was no
significant between-group difference in the risk of relapse
(HR = 0.50, 95% CI: 0.23–1.13, p = 0.10).
Mood and stress outcomes
Additional file 1 presents unadjusted means for all mood
and stress outcomes at baseline, end-of-treatment, and
24 weeks. Fig. 3 presents adjusted means for all mood
and stress outcomes at baseline, end-of-treatment, and
24 weeks. Exact adjusted means and standard errors for
each time point are provided in Additional file 2. Final
models for mood and stress outcomes adjusted for anti-
depressant medication use and for cardiac rehabilitation
attendance.
No significant differences between groups were ob-
served for mean change from baseline to end-of-
treatment for PANAS-PA (η2partial = 0.06, p = 0.08),
PANAS-NA (η2partial = 0.04, p = 0.16), PSS (η
2
partial = 0.03,
p = 0.35), and PHQ-9 (η2partial = 0.05, p = 0.72). Effect
sizes were modest (η2partial 0.03–0.06) but in the hypothe-
sized direction favoring BAT-CS. There were significant,
small to medium effects favoring BAT-CS on baseline to
24-week changes in PANAS-PA (b = 2.73, SE = 1.33,
η2partial = 0.10, p = .04), PANAS-NA (b = −3.02, SE = 1.34,
η2partial = 0.11, p = 0.02), and PSS (b = −1.80, SE = 0.82,
η2partial = 0.11, p = 0.03). No significant effect was ob-
served for change in PHQ-9 from baseline to 24 weeks
(η2partial = 0.07, p = 0.13), but the effect was in the hy-
pothesized direction favoring BAT-CS.
When comparing effects of treatment on changes in
PHQ-9 from baseline to 24 weeks amongst those with
and without likely major depression at baseline, results
indicate a small, non-significant effect favoring BAT-CS
in the PHQ-9 < 10 sub-sample (n = 43; η2partial = 0.09,
p = 0.06) and no effect in the PHQ-9 ≥ 10 sub-sample
(n = 16; η2partial = 0.01, p = 0.27).
BA mechanism
Results indicate a small non-significant between-group
effect favoring BAT-CS on change in BADS at end-of-
treatment (η2partial = 0.05; p = 0.09) and 24 weeks (η
2
par-
tial = 0.05; p = 0.11). Change in BADS from baseline to
end-of-treatment was significantly correlated with con-
current changes in PANAS-PA (rs = .27; p = .04),
PANAS-NA (rs = −.36; p < .01), PHQ-9 (rs = −.56;
p < .001), and PSS (rs = −.51; p < .001). Change in BADS
from baseline to 24-weeks was significantly correlated
with concurrent changes in PHQ-9 (rs = −.55; p < .001)
and PSS (rs = −.40; p < .01). Correlations of change in
BADS from baseline to 24-weeks with concurrent
change in PANAS-PA (rs = .23; p = .11) and PANAS-NA
(rs = −.18; p = .22) were in the hypothesized direction,
but were non-significant.
Discussion
Results support the feasibility of this RCT protocol.
Most patients were willing to be screened and most who
passed the screener were willing to enroll in the study.
We enrolled 1.4 participants per week of recruitment.
Over 80% of participants provided primary outcome data
at all assessment time points. CSQ scores indicated good
Fig. 3 Adjusted mean mood and stress over time
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treatment acceptability in both conditions with mean
CSQ scores above 30 in both conditions.
All smoking outcomes were in the hypothesized direc-
tion, favoring BAT-CS efficacy. However, most were
non-significant, which was expected due to limited
power in this pilot study. Specifically, in fully controlled
models, BAT-CS participants were 1.27 times more
likely than SC participants to be both 7-day PPA abstin-
ent and continually abstinent at 24 weeks post-
discharge. There were larger effects favoring BAT-CS for
continuous abstinence at end-of-treatment (OR =1.82)
and risk of lapse (HR = .38, p = .03) and risk of relapse
(HR = .50, p = .10) in survival analyses. When evaluating
the potential clinical significance of these findings it is
important to note that smoking cessation has a direct,
proximal effect on mortality in this population [6]. Ex-
perts estimate that a cessation treatment that produces a
5% difference in quit rates in this population would have
significant public health value [45]. In adjusted analyses,
the current study indicates a 10.3 and 4.3% between
treatment differences in continuous abstinence at end-
of-treatment and 24-weeks respectively, suggesting po-
tential public health significance. Further, we observed
these differences despite providing a robust control con-
dition (including 1 hour of cessation counseling, free
nicotine patches, and educational materials).
As hypothesized, depressed mood and stress outcomes
favored BAT-CS, with 24-week effect sizes ranging from
η2partial of .07 to.11. Differences were statistically signifi-
cant for positive affect, negative affect, and stress.
Change in depression symptoms at 24 weeks was not
significantly different between groups, but did show a
small to medium effect size favoring BAT-CS. Taken to-
gether, results indicate that BAT-CS has promise for im-
provement in mood and reduction in stress post-ACS.
The observed effect on positive affect is particularly
promising, as lower positive affect has been prospect-
ively linked to both smoking cessation and post-ACS
mortality [9, 10].
We chose to enroll patients with a range of baseline
depression symptoms (i.e., from those asymptomatic to
those with major depression), with the rationale that the
immediate post-ACS period is a high risk time for devel-
opment of depression symptoms [46], especially among
smokers [47], and thus many of those without depres-
sion at baseline could benefit from BA-based prophylac-
tic mood management. When we examined PHQ-9
changes separately for those who had likely major de-
pression at baseline (PHQ ≥ 10 at baseline) and those
that did not (PHQ < 10), the strongest effect was among
those without likely major depression at baseline (η2par-
tial = 0.09), indicating that BAT-CS may be particularly
efficacious for post-ACS depression prevention. This
finding is consistent with existing trials showing that
BA-based mood management can prevent depression in
medical patients [16] and significantly improve mood in
non-depressed individuals [18].
There was almost no 24-week between-group effect on
PHQ-9 change among those with PHQ-9 ≥ 10 at baseline.
This needs to be interpreted with caution given the small
sample for this analysis (n = 16) and existing data indicat-
ing that BA-based treatment is effective for major depres-
sion in medical patients [15]. It may be the case that those
with major depression would benefit from more intensive
counseling than was provided in the current study.
BAT-CS had a promising effect (η2partial = 0.05) on BA’s
purported mechanisms of change measured by the
BADS. While not statistically significant, this finding in-
dicates that BA procedures provided in this study are
likely affecting the targeted behavior. This result was not
surprising given the high goal completion rate observed
(73% in the current study; a previous successful BA for
depression trial found a 58% completion rate using the
same homework compliance measure [13]). We also ob-
served correlations in the expected direction between
change in BADS and change in mood and stress out-
comes consistent with the core of BA theory.
This study has several limitations. First, as a small pilot
study, outcome results should be interpreted as prelimin-
ary. Second, external validity was limited by the fact that
counseling was conducted by Ph.D. providers (which is
not the community standard of care) and by a sample that
was almost 90% non-Hispanic Caucasian (which is not
representative of the overall racial and ethnic diversity of
the U.S.). Third, while our SC control condition exceeds
what is generally available in the community, there was
still significantly more contact time in BAT-CS. Finally,
our longest follow-up was 24 weeks post-ACS, which lim-
ited our ability to examine the sustainability of effects.
Despite these limitations, current results are potentially
impactful as they are the first data on a combined smoking
cessation and mood management counseling intervention
post-ACS. These results also add to the growing literature
indicating that BA is an effective treatment for depressed
mood in medical patients, and this is the second RCT to in-
dicate that BA has promise for the facilitation of smoking
cessation. Follow-up trials of BAT-CS should be powered
to detect between group differences in mood, verified ab-
stinence, and cardiac health at long-term follow-up and
should utilize counselors similar to community providers to
increase external validity. Further, future studies could ex-
plore the utility of pairing BA with counseling targeting
other health behaviors known to be correlated with depres-
sion (e.g., sedentary behavior, medication adherence).
Conclusions
This is the first study to combine smoking cessation and
mood management counseling following a cardiac event.
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Results provide preliminary evidence that combining be-
havioral activation with standard smoking cessation
counseling could be efficacious for this high risk popula-
tion. A larger trial with longer follow-up is warranted.
Additional files
Additional file 1: Unadjusted Mean Mood and Stress Outcomes Over
Time. (DOC 30 kb)
Additional file 2: Adjusted Mean Mood and Stress Outcomes Over
Time.(DOCX 14 kb)
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